Skip to content
Open access

Compact 9dBEs Enable Efficient and Precise Genome Editing in Mammalian Cells and In Vivo

Aug 2026 · Advancement of science · 0 citations · 65 references
Medicine

TL;DR

An efficient Cas9d system (Cas9dUltra) is developed through gRNA and protein engineering, and its base editors (9dBEs) further developed through gRNA and protein engineering, enabling efficient and precise genome editing in human cells.

Abstract

ABSTRACT Despite the promise of DNA base editors for diverse genome editing applications, their utility remains constrained by off‐target effects, which are exacerbated by short spacers in miniature systems and the large size of Cas9‐derived editors, which impedes adeno‐associated virus (AAV) delivery. Here, guided by structural insights into a compact Cas9d nuclease from Deltaproteobacteria, we developed an efficient Cas9d system (Cas9dUltra) through gRNA and protein engineering, and further developed its base editors (9dBEs). Cas9dUltra and 9dBEs enabled efficient and precise genome editing in human cells. Notably, 9dCBE induced premature termination codons in 89% of mouse pups by microinjection, facilitating robust disease modeling. Furthermore, a single AAV delivering 9dCBE achieved efficient Pcsk9 editing and a concomitant reduction in serum LDL‐C levels in mice. Collectively, this study establishes a series of compact, potent genome editing tools poised to advance biological and biomedical translational research.

Read PDF

Similar papers

Open access Jul 2026

Rational and computation-assisted engineering of a compact and efficient StaCas9 genome editor

Natural variation in PAM recognition among SaCas9 orthologs is analyzed and StaCas9 is identified as a compact and efficient nuclease recognizing an NNG PAM, establishing StaCas9 as a high-performance genome-editing tool for therapeutic applications.

Miao-Miao Li, Wenni You, Yuwen Tian et al. · 1 citation
Open access Aug 2026

Compact type II-D Cas9 nucleases for efficient and specific genome editing

Five previously uncharacterized MG102-like Cas9d orthologs are identified that share the hallmark genomic, sequence, and structural features of type II-D Cas9 and establish compact MG102-like Cas9d orthologs as robust and specific genome editors and provide promising, single-AAV– compatible scaffolds for in vivo therap...

Qiaochu Wang, Ahmed Saleh, G. S. Rao et al. · 0 citations
Open access Aug 2026

Compact type II-C Cas9 nucleases with expanded PAM access and high fidelity for therapeutic genome editing

Three previously uncharacterized compact type II-C Cas9 orthologs are identified, and all show a strong deletion-biased repair signature and no detectable editing across 33 predicted off-target sites, expanding the CRISPR targeting space for AAV-deliverable therapeutic editing.

Qiaochu Wang, Sivakrishna Rao Gundra, Rashid Aman et al. · 0 citations
Review Open access Aug 2026

Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications

This review uniquely addresses that gap by presenting an integrated framework that connects molecular design principles with clinical applicability in gRNAs by presenting an integrated framework that connects molecular design principles with clinical applicability.

Masaki Kawamata, S. Niwa, Atsushi Suzuki · 0 citations
Open access Aug 2026

Genome-wide CRISPR screening identifies cellular factors controlling nonviral genome editing efficiency

To systematically map cellular factors constraining nonviral genome editing, influencing uptake and intracellular trafficking, we develop a genome-wide CRISPR screening platform linking perturbation of 19,114 genes to editing outcomes in human cells. We identify six negative regulators of delivery whose depletion incre...

Shivani Saxena, Meha Kabra, Amr A. Abdeen et al. · 0 citations
Mar 2025

Genome-Wide CRISPR Screening Identifies Cellular Factors Controlling Nonviral Genome Editing Efficiency

A novel genome-wide CRISPR screening strategy that will facilitate the systematic engineering of novel nonviral genome editing delivery methods, where the identified novel gene hits can be further used to increase editing efficiency for other therapeutically relevant cell types.

Shivani Saxena, Meha Kabra, Amr A. Abdeen et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.